| Objective : To analyze the expression of ?-catenin in bladder cancer, and systematically review the clinicopathological and prognostic relation between the bladder cancer patients and?-catenin, and to discuss if it would become an effective pharmacological target in bladder cancer treatment.Methods: Searching the subject words and free words in Chinese CNKI literature Library database Version 6.0 (1996 ?September 12, 2016),VIP Chinese Scientific and Technological literature Database resource 6.5 (1989 ?September 12, 2016),Chinese Biological and Medical Literature Resource (CBM) (1978 to September 12, 2016), and the Wanfang data platform on Conferences, journals, papers and so on (1988 to September 12, 2016), and CDSR (The Cochrane Electronic Database for Systematic Review) (Issue 1, 2016); EMBase Database (1974 to September 12, 2016),PubMed / Medline(1975?September 12, 2016),and the Google Academic Web page is searched online and magazine journals are scanned for manual search, the deadline is September 12, 2016. According to the MOOSE (2000 version) principle, we have completed the systematic reviewing process, summarized and analyzed the general information in CCS(case-control study) unquantitatively, and analyzed the data with Revman (5.3 version) tool quantitatively. The results are assessed by OR, HR and 95% CI values. The P-value in Chi2 test is applied to assess the heterogeneity, and the P-value in Z-test is applied to assess the bias.Results: Ultimately 13 paper records are included, which are all case-control studies,containing 862 cases of bladder cancer patients, 76 cases of normal control group, including 8 papers of English records, 5 papers of Chinese language records. The results of our meta-analysis are as follows: (1) The expression of ?-catenin in bladder cancer group is higher than that in normal bladder mucosa group (95% CI = (7.61-50.48); OR = 19.60; P < 0.00001), the difference is statistically significant. (2) The expression of ?-catenin in invasive bladder cancer group is higher than that in superficial bladder cancer group (95% CI = (3.68-7.30); OR = 5.18; P < 0.00001), the difference is statistically significant. (3) The expression of ?-catenin in high-grade carcinoma group is higher than that in low-grade bladder cancer group (95% CI = (2.89-5.71); OR = 4.06; P< 0.00001), the difference is statistically significant. (4) The expression of ?-catenin is not significantly correlated with sex (95% CI = (0.57, 1.96); OR = 1.06; P = 0.85),the difference is not statistically significant. (5) The expression of (3-catenin is not significantly correlated with tumor multiplicity (multiple/ solitary) (95% CI = (0.36, 1.88); OR = 0.82; P = 0.63), and the difference is not statistically significant. (6) The expression level of ?-catenin is correlated with progression-free survival (PFS) of bladder cancer (95% CI = (1.22, 6.14); OR = 2.74; the difference is statistically significant.Conclusions: The result of our meta analysis paper shows that the expression level of?-catenin in bladder cancer group is higher than that in normal bladder mucosa group, that is to say, high expression of ?-catenin may be corralated to the occurrence of bladder cancer. With the increasing expression of ?-catenin, bladder cancer has a higher TNM stage and pathological grade,and PFS is shorter. But it is not significantly correlated to tumor multiplicity and gender. The above analysis suggests that ?-catenin may predict the existence of early canceration, and it may become a biomarker for diagnosis of bladder cancer. |
PDF Full Text Request